Market news

BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.

Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.

Biodesix has seen its fair value estimate move from US$30.83 to US$34.00, which works out to roughly a 10% uplift in the price target range used by analysts. Recent research coverage links this shift to a mix of optimism around revenue momentum and margin potential, along with some caution about execution and the timing of profitability. As you read on, you will see how these moving parts shape the current analyst narrative and what to watch as it evolves from here. Stay updated as the Fair...

Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.

The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Detailed price information for Biodesix Inc (BDSX-Q) from The Globe and Mail including charting and trades.

Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

Biodesix (BDSX) delivered earnings and revenue surprises of +17.44% and +2.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Motley Fool Press Release.

Delivered $26.9 million in revenue, representing 34% growth in Q2 2026;

Biodesix (NASDAQ:BDSX) reported second-quarter 2026 revenue growth of 34% year over year, supported by increased diagnostic test volumes, higher average revenue per test and continued expansion of its commercial organization. Total revenue was $26.9 million for the quarter, while diagnostic testing

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will...